Advanced search
Publication Cover
Expert Review of Vaccines Volume 22, 2023 - Issue 1
Submit an article Journal homepage
720
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study

Yajie Gonga School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Xi Zhanga School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Xue Hana School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Baolan Chena School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Yingxia Xua School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Jitian Huanga School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Wenhan Yanga School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Xi Fua School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Qiancui Wangd Obstetrics and Gynecology, Guangzhou Baiyun District Maternal and Child Health Hospital, Guangzhou, ChinaView further author information
,
Zhongjun Lie Dongguan Hospital, Southern Medical University, Guangzhou, ChinaView further author information
,
Chunfeng Wuf Obstetrics and Gynecology, Shenzhen LongHua District Maternity & Child Healthcare Hospital, Shenzhen, ChinaView further author information
,
Tianran Shena School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Yuting Fana School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Yingshi Daia School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaView further author information
,
Yaping Qiaog Sinovac Biotech Co. Ltd, Beijing, ChinaView further author information
,
Gang Zengg Sinovac Biotech Co. Ltd, Beijing, ChinaView further author information
,
Jikai Zhangh Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, ChinaView further author information
&
Qingsong Chena School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China;b NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China;c Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, Guangdong Pharmaceutical University, Guangzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 956-963 | Received 15 Jul 2023, Accepted 16 Oct 2023, Published online: 27 Oct 2023

References

  • WHO COVID-19 Dashboard. Geneva: World Health Organization. 2020 [cited 2023 Aug]; Available online https://covid19.who.int/
  • Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–192. doi: 10.1016/S1473-3099(20)30843-4
  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
  • Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021;325(23):2370–2380. doi: 10.1001/jama.2021.7563
  • Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021 Sep;225(3):.e303.1–.e303.17. doi: 10.1016/j.ajog.2021.03.023
  • Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641–1647. January 22-October 3, 2020. doi: 10.15585/mmwr.mm6944e3
  • Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320. doi: 10.1136/bmj.m3320
  • Panagiotakopoulos L, Myers TR, Gee J, et al. SARS‐CoV‐2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics—eight U.S. Health care centers. MMWR Morb Mortal Wkly Rep. 2020;69:1355–1359. doi: 10.15585/mmwr.mm6938e2
  • Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):769–775. doi: 10.15585/mmwr.mm6925a1
  • Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021 Aug 1;175(8):817–826. doi: 10.1001/jamapediatrics.2021.1050
  • Tabacco S, Giannini A, Garufi C, et al. Complementemia in pregnancies with antiphospholipid syndrome. Lupus. 2019 Nov;28(13):1503–1509. doi: 10.1177/0961203319882507
  • Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. doi: 10.1056/NEJMoa2107715
  • Paixao ES, Wong KLM, Alves FJO, et al. CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study. BMC Med. 2022 Apr 5;20(1):146. doi: 10.1186/s12916-022-02353-w
  • National Health Commission of the people’s Republic of China.COVID-19 vaccination status. http://www.nhc.gov.cn/xcs/yqjzqk/202212/a87d93dbfbd14fc1b7837f1a20092cbe.shtml.
  • Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010 Jul;17(7):1055–1065. doi: 10.1128/CVI.00131-10
  • Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020 Oct 15;383(16):1544–1555. doi: 10.1056/NEJMoa2024671
  • Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–222. doi: 10.1016/S0140-6736(21)01429-X
  • Xu QY, Xue JH, Xiao Y, et al. Response and duration of serum anti-SARS-CoV-2 antibodies after inactivated vaccination within 160 days. Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554
  • American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric–gynecologic care.Accessed Nov 22, 2021.https://www.acog.org/clinical/clinical-guidance/practice-dvisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care.
  • Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine. N Engl J Med. 2022 May 19;386(20):1910–1921. doi: 10.1056/NEJMoa2200674
  • Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med. 2022 May 12;386(19):1804–1816. doi: 10.1056/NEJMoa2200797
  • Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2022 Apr;28(4):.e612.1–.e612.7. doi: 10.1016/j.cmi.2021.11.010
  • Bian L, Gao Q, Gao F, et al. Impact of the delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021 Oct;20(10):1201–1209. doi: 10.1080/14760584.2021.1976153
  • Muecksch F, Wise H, Batchelor B, et al. Longitudinal Serological analysis and Neutralizing antibody levels in Coronavirus disease 2019 convalescent patients. J Infect Dis. 2021 Feb 13;223(3):389–398. doi: 10.1093/infdis/jiaa659
  • Wang K, Long QX, Deng HJ, et al. Longitudinal dynamics of the Neutralizing antibody response to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis. 2021 Aug 2;73(3):e531–e539. doi: 10.1093/cid/ciaa1143
  • Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022 Apr;22(4):483–495. doi: 10.1016/S1473-3099(21)00681-2
  • Yang YJ, Murphy EA, Singh S, et al. Association of gestational age at Coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with Maternal and umbilical cord antibody levels at delivery. Obstet Gynecol. 2022 Mar 1;139(3):373–380. doi: 10.1097/AOG.0000000000004693
  • Abu-Raya B, Michalski C, Sadarangani M, et al. Maternal immunological adaptation during normal pregnancy. Front Immunol. 2020 Oct 7;11:575197. doi: 10.3389/fimmu.2020.575197
  • Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021 Jun 17;384(24):2273–2282. doi: 10.1056/NEJMoa2104983
  • Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021 Sep;58(3):450–456. doi: 10.1002/uog.23729
  • Sadarangani M, Soe P, Shulha HP, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian national vaccine safety (CANVAS) network cohort study. Lancet Infect Dis. 2022 Aug 11;22(11):S1473-3099(22)00426–1. doi: 10.1016/S1473-3099(22)00426-1

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.